2023 World Conference on Lung Cancer (Posters)-EP06.02. Tertiary Lymphoid Structures Predict Clinical Outcomes of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC

EP06.02. Tertiary Lymphoid Structures Predict Clinical Outcomes of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the prognostic value of tumor-associated tertiary lymphoid structures (TLSs) in resected non-small cell lung cancer (NSCLC) patients who received preoperative neoadjuvant chemoimmunotherapy. The study included 98 patients from two cohorts: neoadjuvant chemoimmunotherapy (N57) and neoadjuvant chemotherapy (N41). TLSs were identified and quantified using H&E staining, and their maturation was characterized using multiplex immunohistochemistry. The results showed that the density of TLSs was higher in the neoadjuvant chemoimmunotherapy cohort compared to the neoadjuvant chemotherapy cohort. Patients with higher TLS density inside the tumor bed region had a more favorable prognosis in both cohorts. However, TLS density outside the tumor bed region showed no significant correlation with clinical outcomes. The analysis also revealed that both primary and mature TLSs were higher in the neoadjuvant chemoimmunotherapy cohort. TLS maturation was found to be an independent predictor of recurrence-free survival in the neoadjuvant chemoimmunotherapy cohort. Overall, the density, spatial distribution, and maturation of TLSs were significantly associated with clinical outcomes and could potentially serve as valuable predicting factors for recurrence-free survival in resectable NSCLC patients receiving neoadjuvant chemoimmunotherapy.

Asset Subtitle

Xinying Xue

Meta Tag

Speaker Xinying Xue

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

prognostic value

tumor-associated tertiary lymphoid structures

TLSs

resected non-small cell lung cancer

NSCLC

preoperative neoadjuvant chemoimmunotherapy

neoadjuvant chemotherapy

density of TLSs

maturation of TLSs

recurrence-free survival